The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Name on ClinicalTrials.gov (link is external) |
A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF) |
|---|---|
| Study Drug | VX-522 mRNA therapy |
| Type of Study Drug | mRNA therapy |
| Study Title | A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy |
| Study Phase | 1 |
| Study Sponsor | Vertex |
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | Adult patients |